Sign In
Get Clay Free →

Suggestions

    Sanket Agrawal

    CEO, 1859 | Growth Driver & Builder

    Sanket Agrawal is a dynamic senior biopharmaceutical leader with a track record of delivering value and mission-critical outcomes in his field. He has experience in advancing novel therapies, leading cross-functional teams, and building sustained winning cultures. Sanket has a diverse background that integrates biopharma drug development and commercialization, organization scaling and transformation, and AIML/Big-Data/Digital. He graduated with a B. Eng. in Delhi College of Engineering, an M. Eng. at the University of Toronto, an MPH at the University of Liverpool, and an MBA at the University of California, Los Angeles - The Anderson School of Management.

    Sanket has held various executive-level positions throughout his career at Amgen, Relsys International, Deloitte Consulting, and Accenture. He is currently the Global Product General Manager of Oncology at Amgen, leading the KRAS Franchise-Sotorasib. Notably, he has also served as Head of Global Commercial, Oncology/Hematology Pipeline, Global Commercial Lead of Oncology, Executive Director of Strategy and Operations (R&D/Regulatory), Chief Business Officer at Relsys International (Oracle Health Sciences), and VP/GM at Relsys International (Oracle Health Sciences). He also co-founded and was principal of SAVtech Solutions.

    Sanket is a lifelong learner, entrepreneur, and compassionate, empowering leader, with a proven ability to succeed across boundaries and roles. He has repeatedly built "new oncology" franchises, immuno and precision - leveraging diagnostics, novel trials, fast-to-market, and business development while optimizing science, speed, and the market. He has also delivered robust commercial results, including portfolio strategy, new product planning, brand positioning, value, innovative go-to-market models, financial, and operational performance.

    Highlights

    Jun 21 · Yahoo Finance
    1859 Welcomes Sanket Agrawal as New CEO - Yahoo Finance
    1859 Welcomes Sanket Agrawal as New CEO - Yahoo Finance
    Jun 21 · Business Wire
    1859 Welcomes Sanket Agrawal as New CEO - Business Wire
    1859 Welcomes Sanket Agrawal as New CEO - Business Wire
    Foundation Medicine Appoints Sanket Agrawal as Chief BioPharma ...

    Related Questions

    What are Sanket Agrawal's key achievements in biotech?
    How did Sanket Agrawal transition from financial analysis to biotech?
    What is the mission of 1859, the company Sanket Agrawal currently leads?
    What strategies has Sanket Agrawal implemented at Foundation Medicine?
    Can you provide more details about Sanket Agrawal's role at Amgen?
    Sanket Agrawal
    Sanket Agrawal, photo 1
    Sanket Agrawal, photo 2
    Get intro to Sanket
    Add to my network

    Experience

    Chief Executive Officer at 1859, since April 2023
    Chief BioPharma Business Officer at Foundation Medicine, July 2021 - March 2023, Held multiple positions at Amgen, including Global Product General Manager, Oncology (KRAS Franchise | LUMAKRAS) and Global Commercial Lead, Oncology (Neulasta and Aranesp)

    Education

    MBA, University of California, Los Angeles - The Anderson School of Management; MPH, University of Liverpool; M. Eng., University of Toronto; B. Eng., Delhi College of Engineering

    Location

    Los Angeles Metropolitan Area